INVOKANA ® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Invokana | Pharmaceuticals